IS2040B - Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja - Google Patents

Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja

Info

Publication number
IS2040B
IS2040B IS5736A IS5736A IS2040B IS 2040 B IS2040 B IS 2040B IS 5736 A IS5736 A IS 5736A IS 5736 A IS5736 A IS 5736A IS 2040 B IS2040 B IS 2040B
Authority
IS
Iceland
Prior art keywords
pharmaceuticals
production
pyrazoline derivatives
pyrazoline
derivatives
Prior art date
Application number
IS5736A
Other languages
English (en)
Other versions
IS5736A (is
Inventor
Rosa Cuberes-Altisent Maria
Maria Berrocal-Romero Juana
Montserrat Contijoch-Llobet Maria
Frigola-Constansa Jordi
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of IS5736A publication Critical patent/IS5736A/is
Publication of IS2040B publication Critical patent/IS2040B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IS5736A 1998-05-29 2000-11-28 Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja IS2040B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801129A ES2137138B1 (es) 1998-05-29 1998-05-29 Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
PCT/ES1999/000156 WO1999062884A1 (es) 1998-05-29 1999-05-27 Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos

Publications (2)

Publication Number Publication Date
IS5736A IS5736A (is) 2000-11-28
IS2040B true IS2040B (is) 2005-08-15

Family

ID=8303969

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5736A IS2040B (is) 1998-05-29 2000-11-28 Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja

Country Status (32)

Country Link
US (2) USRE38963E1 (is)
EP (1) EP1083171B1 (is)
JP (1) JP4633928B2 (is)
KR (1) KR100603666B1 (is)
CN (1) CN1189459C (is)
AR (1) AR018402A1 (is)
AT (1) ATE265437T1 (is)
AU (1) AU752001B2 (is)
BG (1) BG64950B1 (is)
BR (1) BR9910801A (is)
CA (1) CA2333475C (is)
CO (1) CO5031241A1 (is)
CU (1) CU22995A3 (is)
CZ (1) CZ298391B6 (is)
DE (1) DE69916828T2 (is)
DK (1) DK1083171T3 (is)
ES (2) ES2137138B1 (is)
GE (1) GEP20043237B (is)
HU (1) HUP0102102A3 (is)
IS (1) IS2040B (is)
LT (1) LT4879B (is)
LV (1) LV12632B (is)
NO (1) NO316600B1 (is)
NZ (1) NZ508990A (is)
PL (1) PL344412A1 (is)
PT (1) PT1083171E (is)
RU (1) RU2233272C2 (is)
SI (1) SI20580B (is)
SK (1) SK285550B6 (is)
TW (1) TW572898B (is)
WO (1) WO1999062884A1 (is)
ZA (1) ZA200007638B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376519B1 (en) * 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2
ES2236007T3 (es) 1999-12-08 2005-07-16 Pharmacia Corporation Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
ES2174757B1 (es) * 2001-04-06 2003-11-01 Esteve Labor Dr Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
ES2183720B1 (es) * 2001-06-18 2004-01-16 Esteve Labor Dr Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras.
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
US7998996B2 (en) * 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
ES2278503B1 (es) * 2005-06-27 2008-06-16 Laboratorios Del Dr. Esteve, S.A. Epoxidacion de cetonas alfa, beta - insaturadas.
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
ES2312286B1 (es) * 2005-07-15 2010-01-13 Laboratorios Del Dr. Esteve, S.A Uso de compuestos de pirazolina sustituidos para el tratamiento de los trastornos alimentarios que incluyen obesidad o sindrome metabolico en pacientes con una diabetes desarrollada.
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1745781A1 (en) * 2005-07-15 2007-01-24 Laboratorios Del Dr. Esteve, S.A. Combination of pyrazoline type cannabinoid receptor antagonist and statin
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1760078A1 (en) * 2005-07-15 2007-03-07 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds; methods for their preparation
WO2007009702A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1757587A1 (en) * 2005-07-15 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
WO2007009710A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds: methods for their preparation
ES2330716B1 (es) * 2005-07-15 2010-07-09 Laboratorios Del Dr.Esteve, S.A. Formulaciones farmaceuticas de compuestos de pirazolina sustituidos.
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
EP1743638A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
ES2330993B1 (es) * 2005-07-15 2010-07-06 Laboratorios Del Dr. Esteve, S.A. Combinacion de antagonista del receptor de cannabinoides de tipo pirazolina y estatina.
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
AR061623A1 (es) * 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP3009137A1 (en) * 2014-10-16 2016-04-20 Ecuphar N.V. Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2060660B (en) * 1979-10-18 1983-11-23 Bostik Ltd Adhesives containing pyrazoline activators
JPS5818363A (ja) * 1981-07-13 1983-02-02 アメリカン・サイアナミド・カンパニ− 複素環式置換アミノピラゾリン類およびその薬としての用途
DE3765782D1 (de) * 1987-01-05 1990-11-29 Du Pont Pyrazolin mit insektizidischer aktivitaet.
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
CZ292320B6 (cs) * 1995-05-25 2003-09-17 G. D. Searle & Co. Způsob přípravy pyrazolů
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
LV12632B (en) 2001-07-20
ZA200007638B (en) 2001-11-13
USRE38963E1 (en) 2006-01-31
LT4879B (lt) 2002-01-25
DE69916828T2 (de) 2005-04-14
NO316600B1 (no) 2004-03-01
DE69916828D1 (de) 2004-06-03
BG64950B1 (bg) 2006-10-31
ATE265437T1 (de) 2004-05-15
SK18072000A3 (sk) 2001-07-10
CO5031241A1 (es) 2001-04-27
TW572898B (en) 2004-01-21
AU3932999A (en) 1999-12-20
GEP20043237B (en) 2004-05-25
ES2137138A1 (es) 1999-12-01
DK1083171T3 (da) 2004-08-09
NZ508990A (en) 2002-12-20
CZ298391B6 (cs) 2007-09-19
AU752001B2 (en) 2002-09-05
SI20580B (sl) 2007-10-31
BG105005A (en) 2001-08-31
CA2333475A1 (en) 1999-12-09
CU22995A3 (es) 2004-10-12
ES2221382T3 (es) 2004-12-16
AR018402A1 (es) 2001-11-14
ES2137138B1 (es) 2000-09-16
SI20580A (sl) 2001-12-31
CZ20004418A3 (en) 2001-06-13
KR100603666B1 (ko) 2006-07-24
CA2333475C (en) 2009-12-08
LV12632A (lv) 2001-03-20
JP2002516908A (ja) 2002-06-11
PL344412A1 (en) 2001-11-05
HUP0102102A3 (en) 2002-06-28
US6353117B1 (en) 2002-03-05
NO20006029L (no) 2001-01-26
CN1189459C (zh) 2005-02-16
EP1083171B1 (en) 2004-04-28
KR20010052437A (ko) 2001-06-25
HUP0102102A2 (hu) 2002-03-28
LT2000108A (en) 2001-09-25
WO1999062884A1 (es) 1999-12-09
JP4633928B2 (ja) 2011-02-16
NO20006029D0 (no) 2000-11-28
PT1083171E (pt) 2004-09-30
CN1307566A (zh) 2001-08-08
SK285550B6 (sk) 2007-03-01
BR9910801A (pt) 2001-11-27
RU2233272C2 (ru) 2004-07-27
EP1083171A1 (en) 2001-03-14
IS5736A (is) 2000-11-28

Similar Documents

Publication Publication Date Title
IS2040B (is) Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja
IS2215B (is) Setnar fenýlafleiður, framleiðsla þeirra og notkun
IS8698A (is) Súlfónamíðaafleiður, framleiðsla þeirra og notkunþeirra sem lyfja
IS1839B (is) Píperasín afleiður sem hafa verkjastillandi áhrif, framleiðsla og notkun þeirra
NO20024281D0 (no) Indolderivater, fremgangsmåte for fremstilling av de samme og anvendelse derav
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
IL143349A0 (en) Azepinoindole derivatives, the production and use thereof
IS5353A (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
PL365787A1 (en) Heterocyclic compounds, their production and use
HUP0203225A3 (en) Benzodiazepin derivatives, the production and use thereof
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
IS7881A (is) CHK-, PDK- og AKT-hindrandi pýrimidín, framleiðsla þeirra og notkun sem lyfjaefni
HUP0101624A3 (en) New substituted amides, their production and their use
IS2174B (is) Setnar fenýl-píperasín afleiður, framleiðsla þeirra og notkun
NO20030800L (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
IL144370A0 (en) Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
IS7829A (is) Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
IL155624A0 (en) Novel imidazole derivatives, production method thereof and use thereof
ATE505459T1 (de) Dibenzoäb,füazepin-derivate und ihre herstellung
IS5940A (is) Bensófúran afleiður, framleiðsla þeirra og notkun
IS6403A (is) Nýjar heteróarýl afleiður, framleiðsla þeirra og notkun
HU0001397D0 (en) 3-amino-3-arylpropan-1-ol derivatives, production and use thereof
HUP0103358A3 (en) N-substituted azabicycloheptane derivatives, production and use thereof
IL157793A0 (en) Caloporoside derivatives, methods for the production thereof and their use
PL372089A1 (en) Substituted propane-1,3-diamine derivatives and the pharmaceutical use thereof